For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Files Genotropin for Prader-Willi Syndrome
April 26, 2023
- HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
April 26, 2023
- Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
- Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
April 25, 2023
- Santen to Forge Ahead with Structure Reform, Revenue Revamp to Upscale Growth
April 25, 2023
- Actemra Approved in Taiwan for Hospitalized COVID-19 Patients: Chugai
April 25, 2023
- Takeda Installs Chief Tech Officer Role as It Revs Up Digital Drive: CEO
April 24, 2023
- Mitsubishi Sent Letter Agreeing to Call Off Muse Cell License Deal: Researchers
April 24, 2023
- US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
April 24, 2023
- Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
April 21, 2023
- Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Lonsurf-Bevacizumab Combo Gets FDA’s Priority Review in Colorectal Cancer: Taiho
April 20, 2023
- Ono Aims Higher with Aggressive Open Innovation in Drug Discovery
April 19, 2023
- Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
- Nobelpharma Sues Sawai over Nobelzin Patent in Japan
April 19, 2023
- Over 40,000 Patients Given Xocova as of April 9: Shionogi
April 18, 2023
- Rexulti Backed by FDA Advisors for Alzheimer’s Agitation: Otsuka/Lundbeck
April 18, 2023
- Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
April 18, 2023
- BMS Seeks 3rd Line MM Use for Abecma in Japan
April 18, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…